The Levels of H11/HspB8 DNA Methylation in Human Melanoma Tissues and Xenografts Are a Critical Molecular Marker for 5-Aza-2′-Deoxycytidine Therapy

被引：23
作者：
Smith, Cynthia C. [1 ]
Li, Baiquan [1 ]
Liu, Juan [1 ]
Lee, Kie-Sok [1 ]
Aurelian, Laure [1 ]
机构：
[1] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA
来源：
CANCER INVESTIGATION | 2011年 / 29卷 / 06期
基金：
美国国家卫生研究院;
关键词：
Gene expression; Molecular biology; Cutaneous melanoma; Therapy; Prognosis and response predictions; HEAT-SHOCK-PROTEIN; MALIGNANT-MELANOMA; BETA-CATENIN; H11; KINASE; CYCLIN-E; METHYLTRANSFERASE PROMOTER; TUMOR-SUPPRESSOR; TP53; MUTATIONS; CELL-GROWTH; APOPTOSIS;
D O I：
10.3109/07357907.2011.584588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
H11/HspB8 is a functionally distinct small heat shock protein. It causes growth arrest in melanocytes, associated with the inhibition of Cyclin E/Cdk2 and beta-catenin phosphorylation at the transcriptional activity site Ser(552) and is silenced through DNA methylation in 27/35 (77%) melanoma tissues/early cultures. 5-Aza-2 '-deoxycytidine (Aza-C) induces melanoma cell death correlated with the levels of H11/HspB8 DNA methylation (p < .001). In line with low/moderate H11/HspB8 methylation, PI3-K inhibition increases Aza-C-induced cell death. Aza-C inhibits the growth of melanoma xenografts related to the levels of H11/HspB8 methylation, and a nonmethylated/non-TAK1 binding H11/HspB8 mutant confers Aza-C resistance. H11/HspB8 is a potential molecular marker for demethylation therapies.
引用
收藏
页码：383 / 395
页数：13
相关论文
共 58 条
[1]   THE EORTC EARLY CLINICAL-TRIALS COOPERATIVE GROUP EXPERIENCE WITH 5-AZA-2'-DEOXYCYTIDINE (NSC-127716) IN PATIENTS WITH COLO-RECTAL, HEAD AND NECK, RENAL CARCINOMAS AND MALIGNANT MELANOMAS [J].
ABELE, R ;
CLAVEL, M ;
DODION, P ;
BRUNTSCH, U ;
GUNDERSEN, S ;
SMYTH, J ;
RENARD, J ;
VANGLABBEKE, M ;
PINEDO, HM .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (12) :1921-1924
[2]   Axin-mediated CKI phosphorylation of β-catenin at Ser 45:: a molecular switch for the Wnt pathway [J].
Amit, S ;
Hatzubai, A ;
Birman, Y ;
Andersen, JS ;
Ben-Shushan, E ;
Mann, M ;
Ben-Neriah, Y ;
Alkalay, I .
GENES & DEVELOPMENT, 2002, 16 (09) :1066-1076
[3]   A novel gene expressed in human keratinocytes with long-term in vitro growth potential is required for cell growth [J].
Aurelian, L ;
Smith, CC ;
Winchurch, R ;
Kulka, M ;
Gyotoku, T ;
Zaccaro, L ;
Chrest, FJ ;
Burnett, JW .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (02) :286-295
[4]   Relative frequency and morphology of cancers in carriers of germline TP53 mutations [J].
Birch, JM ;
Alston, RD ;
McNally, RJQ ;
Evans, DGR ;
Kelsey, AM ;
Harris, M ;
Eden, OB ;
Varley, JM .
ONCOGENE, 2001, 20 (34) :4621-4628
[5]   RADIATION-INDUCED CELL-CYCLE ARREST COMPROMISED BY P21 DEFICIENCY [J].
BRUGAROLAS, J ;
CHANDRASEKARAN, C ;
GORDON, JI ;
BEACH, D ;
JACKS, T ;
HANNON, GJ .
NATURE, 1995, 377 (6549) :552-557
[6]   Mammalian Hsp22 is a heat-inducible small heat-shock protein with chaperone-like activity [J].
Chowdary, TK ;
Raman, B ;
Ramakrishna, T ;
Rao, CM .
BIOCHEMICAL JOURNAL, 2004, 381 (02) :379-387
[7]   The dual specificity phosphatase cdc25C is a direct target for transcriptional repression by the tumor suppressor p53 [J].
Clair, Selvon St. ;
Manfredi, James J. .
CELL CYCLE, 2006, 5 (07) :709-713
[8]   Aberrant CpG-island methylation has non-random and tumour-type-specific patterns [J].
Costello, JF ;
Frühwald, MC ;
Smiraglia, DJ ;
Rush, LJ ;
Robertson, GP ;
Gao, X ;
Wright, FA ;
Feramisco, JD ;
Peltomäki, P ;
Lang, JC ;
Schuller, DE ;
Yu, L ;
Bloomfield, CD ;
Caligiuri, MA ;
Yates, A ;
Nishikawa, R ;
Huang, HJS ;
Petrelli, NJ ;
Zhang, XL ;
O'Dorisio, MS ;
Held, WA ;
Cavenee, WK ;
Plass, C .
NATURE GENETICS, 2000, 24 (02) :132-138
[9]  
Danam RP, 2001, INT J ONCOL, V18, P1187
[10]   Therapeutic potential of H11 kinase for the ischemic heart [J].
Danan, Ilan J. ;
Rashed, Eman R. ;
Depre, Christophe .
CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (01) :14-29
123456